Duloxetine in the treatment of stress urinary incontinence

被引:13
作者
Michel, Martin C. [1 ]
Oelke, Matthias [2 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pharmacol & Pharmacotherapy, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands
关键词
duloxetine; nausea; norepinephrine; serotonin; stress urinary incontinence;
D O I
10.2217/17455057.1.3.345
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This manuscript reviews the pharmacodynamics and pharmacokinetics of duloxetine and its efficacy and safety in women with stress urinary incontinence. Duloxetine is a selective inhibitor of neuronal serotonin and norepinephrine uptake which increases urethral striated muscle activity and bladder capacity. Duloxetine is readily absorbed and extensively metabolized; cytochrome P450 1A2 (CYP1A2) inhibiting drugs can markedly increase duloxetine exposure. The clinical efficacy of duloxetine has consistently been demonstrated in several randomized, double-blind studies in women with moderate-to-severe stress urinary incontinence, but the additional benefit relative to placebo was moderate. Duloxetine treatment is frequently associated with adverse events such as nausea, dry mouth, fatigue, insomnia and constipation, but serious adverse events are rare. Therefore, duloxetine appears suitable for the treatment of stress urinary incontinence.
引用
收藏
页码:345 / 358
页数:14
相关论文
共 88 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]  
Alhasso A, 2004, COCHRANE DATABASE SY, V1
[3]   Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model [J].
Angulo, J ;
Cuevas, P ;
Cuevas, B ;
Gupta, S ;
de Tejada, IS .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (01) :141-149
[4]   Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters [J].
Béïque, JC ;
Lavoie, N ;
de Montigny, C ;
Debonnel, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 349 (01) :129-132
[5]  
Bo K., 2003, EAU UPDATE SERIES, P145
[6]  
Boy S., 2005, European Urology Supplements, V4, P252, DOI 10.1016/S1569-9056(05)81002-4
[7]  
Bump R, 2005, NEUROUROL URODYNAM, V24, P582
[8]   Mixed urinary incontinence symptoms: Urodynamic findings, incontinence severity, and treatment response [J].
Bump, RG ;
Norton, PA ;
Zinner, NR ;
Yalcin, I .
OBSTETRICS AND GYNECOLOGY, 2003, 102 (01) :76-83
[9]   Cytochrome P450 3A and their regulation [J].
Burk, O ;
Wojnowski, L .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :105-124
[10]   The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression [J].
Bymaster, FP ;
Lee, TC ;
Knadler, MP ;
Detke, MJ ;
Iyengar, S .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (12) :1475-1493